Weight & Measure with Mike and Zach is an obesity podcast featuring conversations with patients, obesity medicine physicians, metabolic & bariatric surgery experts, researchers, dietitians, and advocates. We explore GLP-1 medications, obesity management medications (OMMs), weight loss medications, bariatric surgery, nutrition, body composition, obesity research, patient advocacy, insurance access, and long-term obesity treatment. Every episode combines lived experience with clinical expertise to support patients and healthcare professionals.
Site
RSS
Apple
Données mises à jour le 01/09/2026
Classements récents
Dernières positions dans les classements Apple Podcasts et Spotify.
Liens partagés entre épisodes et podcasts
Liens présents dans les descriptions d'épisodes et autres podcasts les utilisant également.
What Is Person First Language? Obesity, Weight Stigma & Why Words Matter
Saison 1 · Épisode 14
lundi 31 août 2026 • Durée 01:30:49
Should we say “obese person” or “person with obesity”? Does the difference really matter?
In this episode of Weight & Measure with Mike and Zach, we explore person first language, weight stigma, internalized weight bias, and how the words we use can shape the way people living with obesity are treated and how they see themselves.
We're joined by Nina Crowley, PhD, RDN; Renee Rogers, PhD; Leslie Golden, MD; Robyn Pashby, PhD; and Angela Fitch, MD for a wide-ranging conversation about why language matters in obesity care and why person first language shouldn't be something we expect only from physicians and other healthcare professionals.
Person first language means putting the person before the condition: “a person with obesity” rather than “an obese person.” As the panel discusses, obesity is something a person may live with, not the entirety of who they are.
But this episode goes beyond terminology.
What happens when people living with obesity describe ourselves as “I'm obese,” “I've always been the fat one,” or “I'm the funny fat friend”? The panel explores how weight stigma can begin externally and eventually become internalized, influencing identity, expectations, healthcare experiences and the language people use about themselves.
We also discuss the very real consequences of weight bias in healthcare. When people feel stigmatized in medical settings, it can affect trust and even whether they return for care. Zach shares his own experience of having a complication after metabolic & bariatric surgery initially attributed to his behavior rather than investigating whether the treatment itself had failed.
And yes, Zach breaks out the siren, police badge and hat to confront one of the biggest criticisms of conversations like this:
🚨 Are we becoming the “language police”?
The panel tackles the tension between encouraging person first, stigma reducing language and respecting the words individuals choose to use for themselves.
The conversation also explores:
“Obese” vs. “person with obesity”
Why weight stigma in healthcare matters
Internalized weight bias and self identity
Saying “I'm fat” or reclaiming the word “fat”
Being the “funny fat friend”
Person first language vs. language policing
Good food, bad food and cheat meals
How fitness and wellness culture talks about larger bodies
Why obesity treatment isn't a matter of willpower
Why saying a patient “failed” bariatric surgery, medication or a diet places moral judgment on the person
How healthcare professionals, patients and advocates can help change the way we talk about obesity
One of the most powerful ideas from the discussion comes when the panel examines the concept that patients don't fail treatments; treatments can fail patients. The episode challenges the moral judgment embedded in saying someone “failed” bariatric surgery, medication or another obesity treatment and asks why obesity is treated differently from other chronic diseases.
Ultimately, person first language isn't about memorizing a list of words you're allowed or not allowed to say.
It's about becoming more intentional about the language we use, remaining curious about its impact, and remembering that the person comes before the label.
What Are GLP-1 Clinical Trials & How Do I Join One?
Saison 1 · Épisode 14
lundi 24 août 2026 • Durée 01:19:18
What actually happens when you join a GLP-1 or obesity medication clinical trial? And could participating in one give you access to the next generation of obesity treatments before they reach the pharmacy?
On this episode of Weight & Measure with Mike and Zach, Mike Donnelly-Boylen and Zach Niemiec are joined by Dr. Domenica Rubino, founder and director of the Washington Center for Weight Management & Research in Arlington, Virginia.
Dr. Rubino is an obesity medicine physician, endocrinologist, and longtime clinical researcher who has helped study obesity medications throughout the evolution of modern obesity care.
Together, we break down Clinical Trials 101 from the perspective of the people actually volunteering to participate.
We discuss:
• What Phase 1, Phase 2, Phase 3 and Phase 4 clinical trials actually mean • Why developing a medication can take 10–15 years • What happens after you respond to a “Now Enrolling” clinical trial • Screening, informed consent and randomization • Why obesity medication trials still use placebo groups • Your chances of receiving placebo versus an investigational medication • What participating in a clinical trial costs • Whether participants can be compensated for their time and travel • What visits, testing and monitoring look like during a study • What happens if you experience side effects or want to leave a trial • Who is responsible for protecting clinical trial participants • What happens when an investigational medication works but the trial ends • Whether participants can continue receiving a medication after a study • How to decide whether a clinical trial is right for you • How to find legitimate obesity clinical trials on ClinicalTrials.gov • Whether you can still join trials studying retatrutide, CagriSema and other next-generation obesity medications • The rapidly growing research into • Why people who have undergone metabolic & bariatric surgery may have fewer trial options, and why that may be changing• Why you should never stop an effective obesity medication simply to qualify for a clinical trial
What Is Retatrutide?
Saison 1 · Épisode 13
mardi 18 août 2026 • Durée 01:20:28
What is retatrutide, how does it work, and what do the latest retatrutide clinical trial results actually mean for people living with obesity?
In this episode of Weight & Measure with Mike and Zach, Dr. Ania Jastreboff and Ted Kyle join Mike Donnelly-Boylen and Zach Niemiec for a patient-centered deep dive into retatrutide, the investigational GLP-1/GIP/glucagon triple agonist being studied for obesity and type 2 diabetes.
Dr. Jastreboff is a Yale physician-scientist, a leading obesity researcher, and has been deeply involved in the clinical development of retatrutide. She presented the first Phase 3 obesity results from TRIUMPH-1 at the American Diabetes Association Scientific Sessions and is co-author of Enough with Oprah Winfrey.
Ted Kyle is a pharmacist and longtime obesity advocate who brings together obesity science, policy, advocacy and lived experience.
Dr. Jastreboff explains how GLP-1, GIP and glucagon work, why researchers combined all three receptors into one medication, and why activating the glucagon receptor may make sense even though glucagon is commonly associated with increasing blood glucose.
We then break down the TRIUMPH-1 retatrutide results, including:
• How much weight participants lost with retatrutide • Why results may differ between obesity and type 2 diabetes • Retatrutide doses, titration, side effects and discontinuation • Whether everyone needs the highest retatrutide dose • How clinical-trial dosing differs from real-world obesity treatment
We tackle one of the biggest questions surrounding GLP-1 medications: muscle loss.
Dr. Jastreboff explains the important difference between lean mass and skeletal muscle, what body-composition studies can actually measure, and what we know so far about retatrutide compared with semaglutide and tirzepatide.
The conversation goes beyond the number on the scale to explore findings involving knee osteoarthritis, obstructive sleep apnea, liver fat, metabolic health and other complications of obesity.
What Should I Eat on a GLP-1? Dietitians Answer Your Biggest Nutrition Questions
Saison 1 · Épisode 12
lundi 10 août 2026 • Durée 01:19:49
*Note there are some occasional audio issues with this episode, they improve as the episode continues*
What should you actually eat on a GLP-1?
Social media is filled with advice about protein, electrolytes, collagen, greens powders, supplements, and "must-follow" nutrition rules. But how much of that advice is actually supported by evidence?
In this episode of Weight & Measure, Zach Niemiec and Mike Donnelly-Boylen are joined by registered dietitians Gianna Beasley, MS, RD, CPT and Melissa Mitri, MS, RD to separate GLP-1 nutrition facts from fiction.
Whether you're taking Zepbound (tirzepatide), Mounjaro, Wegovy (semaglutide), Ozempic, Saxenda, or another obesity management medication, this conversation provides practical, evidence based guidance to help you build healthy, sustainable nutrition habits.
You'll also hear valuable insights for people who have undergone metabolic & bariatric surgery and are using GLP-1 medications.
The biggest GLP-1 nutrition myths on TikTok, Instagram, Reddit, and Facebook
Why eating less does not always mean better nutrition
How much protein do GLP-1 patients really need?
Electrolytes, collagen, creatine, greens powders, and supplements: what's worth your money?
Why many patients become afraid of food after starting GLP-1 medications
Weight loss plateaus: what they really mean
Why losing weight doesn't automatically mean you're well nourished
When to work with a registered dietitian
Nutrition after metabolic & bariatric surgery while taking GLP-1 medications
What to do if insurance forces you to stop your medication
If you're looking for trustworthy information about GLP-1 nutrition, obesity medicine, bariatric nutrition, weight loss medications, body composition, protein intake, or long-term obesity care, this episode is for you.
GLP-1s Aren't "Skinny Shots": Retatrutide, CKM & the Future of Obesity Care
Saison 1 · Épisode 11
lundi 3 août 2026 • Durée 01:12:07
GLP-1 medications have become some of the most talked about drugs in medicine—but are they really just "skinny shots"?
In this episode of Weight & Measure with Mike and Zach, we sit down with two of the most respected voices in obesity care to separate fact from fiction and explore where obesity treatment is heading next.
Joining us are:
Ted Kyle, RPh, MBA – Founder of ConscienHealth and one of the nation's leading advocates for evidence-based obesity policy and public education.
Katherine Saunders, MD, DABOM – Obesity Medicine physician and nationally recognized expert on GLP-1 medications, emerging obesity therapies, and comprehensive obesity care.
Together, we discuss why GLP-1 medications are changing much more than body weight, how obesity medicine is shifting its focus toward overall health, and why the next generation of therapies—including retatrutide—could reshape obesity treatment once again.
• Why calling GLP-1s "skinny shots" misses the bigger picture. • How GLP-1 medications are changing healthcare, society, and the conversation around obesity. • Why obesity is a chronic disease—and why that idea still faces resistance. • What CKM (Cardiovascular, Kidney, and Metabolic Health) means and why it's becoming a new framework for treating patients. • The latest research on access to obesity care and what the "secret shopper" study revealed. • How social media has influenced public understanding of obesity, for better and for worse. • The science behind glucagon agonists, amylin agonists, and combination therapies. • Why retatrutide has generated so much excitement—and why experts caution that more weight loss doesn't automatically mean a better medication. • How GLP-1 medications fit alongside metabolic and bariatric surgery as part of comprehensive, individualized obesity care. • What today's obesity experts hope we'll understand differently about GLP-1s twenty years from now.
What were the biggest conversations coming out of the OAC Your Weight Matters Conference?
In this special episode of Weight & Measure, hosts Mike Donnelly Boylen and Zach Niemiec are joined by an outstanding panel to discuss the most impactful moments from the conference, including the latest conversations in obesity medicine, GLP-1 medications, bariatric surgery, patient advocacy, exercise science, and comprehensive obesity care.
Joining us are:
Jay Hutchins, Host of the Cheers to This Podcast
Gianna Beasley, RD, CPT
Renee Rogers, PhD
Robyn Pashby, PhD
Together, we discuss:
Key takeaways from the OAC Your Weight Matters Conference
The future of obesity medicine and comprehensive obesity care
The role of GLP-1 medications and other obesity management medications
Bariatric surgery and long-term obesity treatment
Exercise, nutrition, and behavior change for people living with obesity
Patient advocacy and reducing weight stigma
Why obesity is a chronic disease that deserves evidence-based care
The latest research and conversations shaping the future of obesity care
Whether you're a person living with obesity, a bariatric patient, obesity medicine clinician, registered dietitian, exercise professional, or healthcare provider, this episode offers practical insights from one of the nation's leading obesity conferences.
Topics Covered:
Obesity
Obesity Medicine
GLP-1 Medications
Starting a GLP-1 or having Bariatric Surgery? Get the care you deserve.
Saison 1 · Épisode 10
lundi 20 juillet 2026 • Durée 01:23:05
Do You Have Comprehensive Obesity Care? GLP-1s, Obesity Medicine & Bariatric Surgery Explained
What does comprehensive obesity care actually mean?
For many people, obesity treatment is often reduced to a single intervention, whether that's a diet, an obesity management medication (OMM), or metabolic & bariatric surgery. But effective obesity care is much more than any one treatment. It is a personalized, evidence-based approach that combines medical care, nutrition, physical activity, behavioral health, sleep, medications, surgery when appropriate, and long-term follow-up to support lifelong health.
In this episode of Weight & Measure with Mike and Zach, we're joined by Dr. Carolynn Francavilla, MD, MFOMA, DABOM, the 2025 Obesity Medicine Association Clinician of the Year, and Dr. Rebecca Andrick, DO, DABOM, FOMA, two leading obesity medicine specialists who are helping redefine what patient-centered obesity care should look like.
Together, we answer one of the most important questions facing patients today:
Do you have comprehensive obesity care?
We explore why obesity is recognized as a chronic disease, how obesity medicine has evolved beyond "eat less and move more," and why long-term success often requires multiple evidence-based tools working together. We also discuss where obesity management medications (OMMs), including GLP-1 and GLP/GIP therapies, fit into treatment, how metabolic & bariatric surgery complements medical care, and why individualized treatment plans lead to better patient outcomes.
Whether you're living with obesity, considering treatment options, supporting a loved one, or working in healthcare, this conversation will help you better understand what high-quality, comprehensive obesity care should include and what every patient deserves from their healthcare team.
• What comprehensive obesity care really means • Why obesity is a chronic disease, not a personal failure• How obesity medicine has evolved beyond "eat less and move more"• Where obesity management medications (OMMs), including GLP-1 and GLP/GIP therapies, fit into treatment• The role of metabolic & bariatric surgery in comprehensive obesity care• Why multidisciplinary care leads to better long-term outcomes• Nutrition, physical activity, sleep, and behavioral health as essential parts of treatment• How patients can advocate for evidence-based obesity care• Weight bias, stigma, and improving the patient experience• Measuring success beyond the number on the scale• The future of obesity medicine and comprehensive obesity care
GLP-1 TikTok: Helping or Hurting Patients? | Wegovy, Zepbound, Ozempic & Social Media
Saison 1 · Épisode 9
jeudi 9 juillet 2026 • Durée 01:17:33
Is GLP-1 TikTok helping or hurting patients?
Millions of people living with obesity turn to TikTok every day for information, support, motivation, and community. But as obesity management medications like Wegovy®, Zepbound®, Ozempic®, and Mounjaro® become increasingly common, social media has also become one of the most influential sources of obesity treatment information.
So who is shaping the conversation?
In this episode of Weight & Measure, hosts Mike Donnelly-Boylen and Zach Niemiec are joined by Dr. Danna Kashlan of Johns Hopkins Medicine and Dr. Lindsey Ogle for an important discussion inspired by Dr. Kashlan's research presented at the 2026 American Diabetes Association Scientific Sessions.
Her research, "Who Shapes the GLP-1 Narrative on TikTok?", examined highly engaged GLP-1 content and found that patients, not healthcare professionals, are driving much of the conversation online.
Together, we explore the growing influence of social media on obesity care and ask an important question:
Is GLP-1 TikTok helping patients, hurting patients, or both?
• Why GLP-1 TikTok has become one of the largest online communities for people living with obesity
• The benefits of peer support, shared lived experience, and patient advocacy
• The risks of misinformation, comparison culture, unrealistic expectations, and viral health advice
• How healthcare professionals can better understand the online communities their patients participate in
• How patients can identify trustworthy obesity medicine information online
• Why lived experience and evidence based medicine should work together, not compete
When Obesity Medicine Gets Personal: Physicians Living with Obesity on GLP-1s, Bariatric Surgery, Med School & Patient Care
Saison 1 · Épisode 8
mardi 23 juin 2026 • Durée 01:26:31
What happens when the obesity medicine physician is also living with obesity?
In this episode of Weight & Measure, hosts Mike Donnelly-Boylen and Zach Niemiec are joined by Dr. Matthea Rentea, Dr. Catherine Toomer, and Dr. Brianna Bingham for an honest conversation about obesity, GLP-1 medications, bariatric surgery, weight stigma, and the realities of treating a disease while also living with it.
Together, they discuss their personal obesity journeys, what medical education often gets wrong about obesity, and how lived experience has shaped the way they care for patients. The conversation explores obesity treatment, long-term weight management, bariatric surgery, GLP-1 medications, and the future of obesity medicine.
Topics include:
• What medical education still gets wrong about obesity • How lived experience changes patient care • GLP-1 medications and obesity treatment • Zepbound, Mounjaro, Wegovy, and Ozempic • Tirzepatide and semaglutide • Bariatric and metabolic surgery • Weight stigma in healthcare • Patient-centered obesity care • Long-term weight management • Obesity advocacy • The future of obesity treatment
Dr. Matthea Rentea shares lessons from her personal journey and insights from hundreds of conversations through The Obesity Guide Podcast.
Dr. Catherine Toomer discusses maintaining significant weight loss for more than twenty years while helping patients navigate multiple generations of obesity treatment.
Dr. Brianna Bingham offers her perspective on bariatric surgery, obesity care, and how personal experience influences clinical practice.
Whether you are taking a GLP-1 medication, considering bariatric surgery, living with obesity, supporting a loved one, or working in healthcare, this episode provides a perspective rarely heard in medicine: physicians discussing obesity through both clinical expertise and lived experience.
GLP-1 Maintenance: Why Keeping Weight Off Is Harder Than Losing It
mercredi 17 juin 2026 • Durée 01:29:38
You Lost the Weight. Now What? GLP 1 Maintenance, Mindset, and Long Term Success
Many people focus on how to lose weight.
Far fewer talk about what happens after.
For many individuals using GLP 1 medications, pursuing Bariatric & Metabolic Surgery, or making significant lifestyle changes, reaching a goal weight is not the end of the journey. It is the beginning of a new challenge: maintaining weight loss long term.
In this episode of Weight & Measure with Mike and Zach, we explore one of the most important and least discussed topics in obesity care: long term weight maintenance.
Joining us are:
• Leslie Golden, MD • Robyn Pashby, PhD
Together, we discuss why weight recurrence happens, why it is not simply a matter of willpower, and what people can do to build sustainable strategies for long term success.
Topics include:
• Why keeping weight off is often harder than losing it • The biology behind weight maintenance and weight recurrence • GLP 1 maintenance strategies after active weight loss • Long term use of obesity medications • Hunger, metabolism, and the body's response to weight loss • The psychological challenges of maintaining weight loss • Identity changes after significant weight loss • Fear of weight recurrence and how to navigate it • Perfectionism and all or nothing thinking • Emotional eating, stress, and coping strategies • Building sustainable habits for long term success • Bariatric and metabolic surgery considerations during maintenance • Why body composition may matter more than the scale • The mindset shift from losing weight to living at a lower weight
One of the most overlooked realities of obesity treatment is that maintenance is not just a physical challenge. It is also a psychological one.
How do you trust yourself after years of weight cycling?
Podcasts Similaires Basées sur le Contenu
Découvrez des podcasts liées à Weight & Measure. Explorez des podcasts avec des thèmes, sujets, et formats similaires. Ces similarités sont calculées grâce à des données tangibles, pas d'extrapolations !
amylin-based medications, dual agonists and triple agonists
Dr. Rubino also shares an important warning for anyone eager to access the newest investigational obesity medications: a clinical trial isn't simply a way to get a new drug early. Participants need to understand the study, the possibility of receiving placebo, the potential risks and benefits, and whether participation makes sense for their individual situation.
Clinical trials are responsible for much of what we know about obesity treatment today. Behind every headline about a new medication are thousands of people who volunteered to help researchers answer those questions.
This episode is about understanding both the science and the people who make that science possible.
🎙️ Guest: Dr. Domenica Rubino 🎙️ Hosts: Mike Donnelly-Boylen & Zach Niemiec
Subscribe to Weight & Measure with Mike and Zach on YouTube, Apple Podcasts, Spotify and Amazon Music.
We also ask whether comparing retatrutide vs tirzepatide vs metabolic & bariatric surgery misses the bigger point. Could the future of obesity care involve choosing and combining treatments based on the individual rather than asking which treatment “wins”?
Ted explains Lilly’s planned Biologics License Application (BLA) for retatrutide, what biologic status could mean for future competition and why we still cannot assume what retatrutide will eventually cost.
We also discuss expanded access to retatrutide before FDA approval, who it is intended for, and why retatrutide remains an investigational medication.
Finally, Dr. Jastreboff connects the science to Enough, her book with Oprah Winfrey.
What is the “Enough Point”? Is the goal of obesity treatment always greater weight loss? Or should success be individualized around health, function, quality of life and the outcomes that matter to the person receiving treatment?
What is retatrutide? How does it compare with tirzepatide? Does retatrutide cause muscle loss? When will retatrutide be available? And what do we still not know?
This episode separates what the science actually shows from the speculation surrounding one of the most talked-about obesity medications in development.
More Science. Less Stigma.
Retatrutide is investigational and is not FDA approved.
Whether you're living with obesity, taking a GLP-1 medication, considering metabolic and bariatric surgery, following the latest research on retatrutide, or simply trying to better understand obesity as a chronic disease, this conversation provides practical, evidence-based insights grounded in science—not stigma.
• Ted Kyle, RPh, MBA • Katherine Saunders, MD, DABOM
GLP-1 • GLP-1 medications • Retatrutide • Tirzepatide • Semaglutide • Ozempic • Wegovy • Mounjaro • Zepbound • Obesity Medicine • Obesity Care • Chronic Disease • CKM • Cardiovascular Kidney Metabolic Health • Metabolic and Bariatric Surgery • Weight Loss Medications • Anti-Obesity Medications • Emerging Obesity Therapies • Glucagon Agonists • Amylin Agonists • Comprehensive Obesity Care • Weight Bias • Obesity Advocacy • Patient Advocacy • Evidence-Based Medicine
If you enjoyed this conversation, be sure to subscribe to Weight & Measure on YouTube and follow us on Spotify, Apple Podcasts, and Amazon Music so you never miss future conversations exploring the science of obesity, GLP-1 medications, metabolic and bariatric surgery, and the future of evidence-based obesity care.
More Science. Less Stigma.
Bariatric Surgery
Metabolic & Bariatric Surgery
Comprehensive Obesity Care
Exercise Science
Nutrition
Patient Advocacy
Weight Stigma
OAC Your Weight Matters Conference
Obesity Action Coalition (OAC)
Chronic Disease
Lifestyle Medicine
Weight Management
Subscribe to Weight & Measure on Apple Podcasts, Spotify, Amazon Music, or wherever you listen to podcasts for conversations with leading experts in obesity medicine, bariatric surgery, nutrition, advocacy, and metabolic health.
Dr. Carolynn Francavilla, MD, MFOMA, DABOM Board-Certified Family Physician 2025 Obesity Medicine Association Clinician of the Year
Dr. Rebecca Andrick, DO, DABOM, FOMA Board-Certified Obesity Medicine Physician Fellow of the Obesity Medicine Association
Mike Donnelly-Boylen Zachary Niemiec, MBA
🎧 Subscribe to Weight & Measure
Follow Weight & Measure on your favorite podcast platform for conversations with leading physicians, researchers, registered dietitians, patient advocates, and individuals with lived experience as we explore the science of obesity, obesity medicine, GLP-1 medications, metabolic & bariatric surgery, nutrition, advocacy, and long-term obesity care.
If you enjoyed this episode, please subscribe, leave a rating and review, and share it with someone who could benefit from learning more about comprehensive obesity care.
• The future of obesity care in the age of social media
Whether you're taking Wegovy®, Zepbound®, Ozempic®, Mounjaro®, another obesity management medication, considering treatment, supporting someone living with obesity, creating health content online, or working in obesity medicine, this episode offers an honest and balanced conversation about one of the fastest growing influences on modern obesity care.
Weight & Measure with Mike and Zach is a live panel series bringing together leading obesity medicine physicians, researchers, advocates, and people with lived experience for thoughtful conversations that bridge science, clinical care, and the patient experience.
New episodes premiere live on On The Pen before being released on all major podcast platforms.
Amazon Music https://music.amazon.com/podcasts/183597e3-d4de-4d93-a7c0-55f0cc6018bd/weight-measure?ref=dm_sh_iwSFqgfpShmLX8vRQR2ZxyJ5y
Download the ProCare Health Non-Surgical Weight Loss & Obesity Management Guide to support patients using obesity management medications (OMMs): https://procarenow.com/pages/non-surgical-weight-loss-obesity-management-program
FREE EDUCATIONAL RESOURCE FOR HEALTHCARE PROFESSIONALS
If your practice provides non-surgical weight loss, obesity medicine, GLP-1 therapy, or comprehensive obesity care, download ProCare Health's Non-Surgical Weight Loss & Obesity Management Guide:
Weight & Measure is hosted by Mike Donnelly-Boylen and Zach Niemiec. The podcast brings together people living with obesity, healthcare professionals, researchers, advocates, and industry leaders to explore obesity care, obesity medicine, bariatric surgery, GLP-1 medications, patient advocacy, weight stigma, and the future of treatment.
How do you stop living in fear of regaining the weight you worked so hard to lose?
Whether your journey includes Wegovy, Zepbound, Mounjaro, GLP 1 medications, Bariatric & Metabolic Surgery, nutrition changes, physical activity, or a combination approach, this episode provides evidence informed insights to help you navigate the next phase of your journey.
Weight & Measure with Mike and Zach is a live conversation series bringing together patients, clinicians, researchers, and advocates to discuss obesity medicine, GLP 1 medications, Bariatric & Metabolic Surgery, patient advocacy, and long term health.
Keywords: GLP 1 maintenance, weight maintenance, weight loss maintenance, weight recurrence, obesity medicine, obesity care, Ozempic, Wegovy, Zepbound, Mounjaro, Foundayo, semaglutide, tirzepatide, obesity treatment, Bariatric Surgery, Metabolic Surgery, health psychology, emotional eating, weight cycling, body composition, obesity medications, long term weight loss.
